Q1 FY27 results: Revenue up 7% YoY but consolidated PAT falls about 53%
SYMBIOTEC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.0 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Symbiotec Pharmalab, which listed on NSE and BSE on September 1, 2026 after a Rs 17,570 million IPO, posted its first quarterly results as a listed company for Q1 FY27. Consolidated revenue from operations rose 7.4% YoY to Rs 2,181.5 million, but net profit fell about 53% to Rs 140.5 million from Rs 299.2 million a year earlier. Profit before tax margin compressed sharply to around 8% from 22%. There were no exceptional items this quarter. On a standalone basis, net profit grew 5.7% to Rs 470 million on revenue of Rs 2,108 million. Auditor SRBC issued an unmodified limited review report.
Consolidated earnings nearly halved YoY on sharp margin compression despite modest revenue growth; standalone held steady. Next quarter update on IPO proceeds use will be in focus.